



CURRICULUM VITAE DARIA CAPECE

PERSONAL INFORMATION	Daria Capece Department of Biotechnological and Applied Clinical Sciences (DISCAB) L'Aquila, 67100, Italy daria.capece@univaq.it
CURRENT POSITION	RTDb
EDUCATION OTHER QUALIFICATIONS	PhD in Biotechnology November 2006 - March 2010 University of L'Aquila Master's degree in Medical Biotechnology October 2004 - July 2006 University of L'Aquila Bachelor's degree in Biotechnology October 2001 - July 2004 University of L'Aquila
ACADEMIC APPOINTMENTS	Imperial College London January 2013 – May 2020 Research Associate, Centre for Cell Signalling and Inflammation Historical Museum of Physics & Research Centre "Enrico Fermi" February 2011- December 2012 Post-doctoral fellow University of L'Aquila February 2010 - January 2011 Post-doctoral fellow at Department of Biotechnological and Applied Clinical Sciences
CLINIC APPOINTMENTS	N/A



TEACHING EXPERIENCE	<p>L'Aquila University 2020-2021 Conventional and advanced diagnostic strategies [B0407], Master Course in Medical Biotechnology (LM9).</p> <p>Imperial College London 2017-2019 MSc Molecular Medicine</p>
RESEARCH ACTIVITIES	<p>My research focuses on the molecular mechanisms underlying tumorigenesis, with a special interest in NF-κB signalling during inflammation and cancer cell metabolic adaptation. I have been working on several projects involving the identification and characterization of NF-κB target genes, in particular those mediating the anti-apoptotic and bioenergetic functions of NF-κB in cancer, with the aim of developing new anticancer therapeutics safely targeting NF-κB downstream effectors.</p>
RESPONSIBILITY IN ACADEMIC ACTIVITIES	<p>Member of Research Committee of DISCAB, L'Aquila University</p>
EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP	<p>Italian Association of Cell Culture (AICC) 2009-2012, 2017</p> <p>Italian Society of translational research and medical professions (S.I.R.T.E.P.S.) 2019 - Today</p> <p>Review Editor in Cancer Metabolism for the journal "Frontiers in Oncology" 2019 - Today</p> <p>Reviewer Member Board for the journal "Cancers" 2019 - Today</p>
SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS	<p>Scopus Author ID: 35301650900 https://orcid.org/0000-0003-3126-2014</p>
SELECTED PUBLICATIONS	<p>NF-κB and mitochondria cross paths in cancer: mitochondrial metabolism and beyond. Capece D, Verzella D, Di Francesco B, Alesse E, Franzoso G and Zazzeroni F. <i>Semin Cell Dev Biol.</i> 2020; 98:118-128.</p> <p>Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. Tornatore L, Capece D*, D'Andrea A, Begalli F, Verzella D, et al. <i>Toxicol Rep.</i> 2019; 6:369-379. *, co-first author.</p>



	<p>Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma. Tornatore L, Capece D*, D'Andrea A, Begalli F, Verzella D, et al. <i>Br J Haematol.</i> 2019; 185(3):588-592. *, co-first author.</p> <p>Turning an old GADDget into a troublemaker. Capece D, D'Andrea D, Verzella D, Tornatore L, Begalli F, et al. <i>Cell Death & Differentiation</i> 2018; 25:640–642.</p> <p>GADD45β loss ablates innate immunosuppression in cancer. Verzella D, Bennett J, Fischietti M, Thotakura AK, Recordati C, Pasqualini F, Capece D, et al. <i>Cancer Res.</i> 2018; 78(5):1275-1292.</p> <p>Cancer-selective targeting of the NF-κB survival pathway with Gadd45β/MKK7 inhibitors. Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, et al. <i>Cancer Cell.</i> 2014; 26(4):495-508.</p>
--	--

L'Aquila, 28/02/2021